Advertisement

Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study

Yoav H. Messinger, Paul S. Gaynon, Richard Sposto, Jeannette van der Giessen, Elena Eckroth, Jemily Malvar and Bruce C. Bostrom for the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium

Article Information

Citation 
vol. 120 no. 2 285-290
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted April 10, 2012
  • Accepted May 23, 2012
  • Published online July 12, 2012.

Article Versions


Contributors 
  • Yoav H. Messinger, 1Children's Hospitals and Clinics of Minnesota, Hematology/Oncology, Minneapolis, MN;
  • Paul S. Gaynon, 2Division of Hematology/Oncology, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, CA; 3Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and
  • Richard Sposto, 3Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and 4Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA
  • Jeannette van der Giessen, 3Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and
  • Elena Eckroth, 3Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and
  • Jemily Malvar, 3Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA; and
  • Bruce C. Bostrom, 1Children's Hospitals and Clinics of Minnesota, Hematology/Oncology, Minneapolis, MN;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output